Ex­clu­sive: Sama Fer­til­i­ty rais­es $3.8M to make IVF more ac­ces­si­ble

Last week
Financing
Health Tech

Un­nat­ur­al Prod­ucts taps ar­genx's help for ringed mol­e­cules, ex­pands in­ter­nal work in­to obe­si­ty

Last week
Startups
Deals

Beck­ley touts pos­i­tive mid-stage psy­che­del­ic da­ta fol­low­ing atai merg­er plans

Last week
R&D

Ex­clu­sive: Bob Langer-found­ed Syn­tis Bio gets $33M Se­ries A for obe­si­ty, rare dis­ease drugs

Last week
Financing
Startups

Pro­tag­o­nist un­veils 'triple-G' obe­si­ty pill, but hu­man tri­als are near­ly a year away

Last week
R&D

Supreme Court pass­es on Ok­la­homa’s drug mid­dle­men spat

Last week
Pharma
Law

Pfiz­er ends Phase 1b/2 tri­al for fi­nal Tril­li­um CD47 drug

Last week
R&D

Sage plans to lay off al­most every em­ploy­ee af­ter ink­ing Su­per­nus deal

Last week
People
Deals

Arc­turus claims Phase 2 suc­cess in first da­ta since shift to mR­NA ther­a­peu­tics, in­vestor re­ac­tion is mut­ed

Last week
R&D

CBER chief Prasad sug­gests Covid vac­cine harms may out­weigh ben­e­fits in 'low-risk pop­u­la­tion­s'

Last week
R&D
Pharma

Ex­clu­sive: Khosla Ven­tures backs start­up sell­ing ‘ther­a­peu­tic plas­ma ex­change’ at longevi­ty clin­ics

Last week
Startups
R&D

Am­gen’s stom­ach can­cer drug boosts sur­vival in Phase 3, but oc­u­lar side ef­fects leave ques­tions

Last week
R&D

Ap­ple Tree Part­ner­s' biotechs 'face im­mi­nent col­lapse' as firm bat­tles Russ­ian in­vestor in court

Last week
Financing
Startups

IN­mune Bio’s Alzheimer’s drug fails Phase 2; Bridge­Bio sells some AT­TR-CM roy­al­ties

Last week
News Briefing

Ab­b­Vie bags Cap­stan’s in vi­vo CAR-T work with $2.1B buy­out deal

Last week
Deals
Bioregnum

Hik­ma pledges $1B to ex­pand US man­u­fac­tur­ing pres­ence

Last week
Pharma
Manufacturing

Uni­cy­cive gets a CRL for chron­ic kid­ney dis­ease pill as third-par­ty pro­duc­tion is­sues linger

Last week
Pharma
Manufacturing

Mod­er­na's Phase 3 flu vac­cine ef­fi­ca­cy in line with com­peti­tors, tee­ing up new sub­mis­sions

Last week
R&D
Pharma

Ope­nAI-backed start­up re­leas­es new AI mod­els, claim­ing top per­for­mance in mak­ing an­ti­bod­ies

Last week
Startups
AI

Sources say FDA com­mis­sion­er sought re­jec­tion of KalVista’s rare dis­ease drug; FDA looks in­to Sarep­ta’s Duchenne ...

Last week
Weekly

J&J dealt blow in fight over its 340B re­bate mod­el

Last week
Pharma
Law

FDA gives drug­mak­ers more time to sub­mit im­pu­ri­ty da­ta

Last week
R&D
Pharma

FDA loosens safe­ty re­quire­ments for CAR-Ts in move to boost ac­cess

Last week
R&D
FDA+

CEOs push EU to in­clude cell, gene ther­a­py in­cen­tives in Biotech Act

Last week
Cell/Gene Tx
Law
First page Previous page 1234567 Next page Last page
A service from the Financial Times